CMS’ Off-Label Coverage Decision For Colorectal Cancer Drugs Could Include Registries
This article was originally published in The Pink Sheet Daily
Executive Summary
The Centers for Medicare & Medicaid Services’ national coverage determination for oncologics, including Avastin and Erbitux, could be modeled on coverage for PET scans in Alzheimer’s patients, which includes trial registries. CMS expects to complete its coverage determination by Dec. 31.
You may also be interested in...
CMS To Fund Clinical Trials Evaluating Off-Label Use Of Avastin, Erbitux
Under the agency’s proposed national coverage decision for colorectal therapies, CMS will fund costs of experimental drugs and routine care in nine National Cancer Institute trials. Use of Avastin in patients with colorectal cancer in the adjuvant setting and use of Erbitux in head and neck cancers are among the indications being studied in the NCI trials.
CMS To Fund Clinical Trials Evaluating Off-Label Use Of Avastin, Erbitux
Under the agency’s proposed national coverage decision for colorectal therapies, CMS will fund costs of experimental drugs and routine care in nine National Cancer Institute trials. Use of Avastin in patients with colorectal cancer in the adjuvant setting and use of Erbitux in head and neck cancers are among the indications being studied in the NCI trials.
Roche Touts Benefit Of Health Economic Data For Targeted Cancer Therapies
Reimbursement for Genentech's Avastin indicates the value of health economic data, Roche Worldwide Pharmaceuticals Head William Burns said